Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2070401 | PMC |
| http://dx.doi.org/10.1136/bmj.2.4730.527 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Australian Gonococcal Surveillance Program, 1 April to 30 June 2024.
Commun Dis Intell (2018)
January 2025
The World Health Organization Collaborating Centre for STI and AMR and Neisseria Reference Laboratory, NSW Health Pathology, Microbiology, Prince of Wales Hospital, Randwick, NSW, 2031, Australia.
The Australian National Neisseria Network (NNN) comprises reference laboratories in each state and territory that report data on antimicrobial susceptibility testing to an agreed group of antimicrobial agents for the Australian Gonococcal Surveillance Programme (AGSP). The AGSP data are presented quarterly in tabulated form, as well as in the AGSP annual report. This report presents national gonococcal antimicrobial resistance surveillance data from 1 April to 30 June 2024.
View Article and Find Full Text PDFAustralian Gonococcal Surveillance Program, 1 January to 31 March 2024.
Commun Dis Intell (2018)
January 2025
The World Health Organization Collaborating Centre for STI and AMR and Neisseria Reference Laboratory, NSW Health Pathology, Microbiology, Prince of Wales Hospital, Randwick, NSW, 2031, Australia.
The Australian National Neisseria Network (NNN) comprises reference laboratories in each state and territory that report data on antimicrobial susceptibility testing to an agreed group of antimicrobial agents for the Australian Gonococcal Surveillance Programme (AGSP). The AGSP data are presented quarterly in tabulated form, as well as in the AGSP annual report. This report presents national gonococcal antimicrobial resistance surveillance data from 1 January to 31 March 2024.
View Article and Find Full Text PDFRationale and Ethical Assessment of an Oropharyngeal Gonorrhoea Controlled Human Infection Model.
J Infect Dis
January 2025
Department of Infectious Diseases, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.
Infection with Neisseria gonorrhoeae, the causative agent of gonorrhoea, causes significant morbidity worldwide and can have long-term impacts on reproductive health. The greatest global burden of gonorrhoea occurs in low- and middle-income settings. Global public health significance is increasing due to rising antimicrobial resistance (AMR), which threatens future gonorrhoea management.
View Article and Find Full Text PDFGerman evidence- and consensus-based guideline on the management of penile urethritis.
J Dtsch Dermatol Ges
January 2025
Department of Infection Epidemiology, Robert Koch Institute, Berlin, Germany.
Urethritis is a common condition predominantly caused by sexually transmitted pathogens such as Chlamydia trachomatis, Neisseria gonorrhoeae, and Mycoplasma genitalium. It is not possible to differentiate with certainty between pathogens on the basis of clinical characteristics alone. However, empirical antibiotic therapy is often initiated in clinical practice.
View Article and Find Full Text PDFRational selection of TbpB variants yields a bivalent vaccine with broad coverage against Neisseria gonorrhoeae.
NPJ Vaccines
January 2025
Department of Molecular Genetics, Temerty Faculty of Medicine, University of Toronto, Toronto, Canada.
Neisseria gonorrhoeae is an on-going public health problem due in part to the lack of success with efforts to develop an efficacious vaccine to prevent this sexually transmitted infection. The gonococcal transferrin binding protein B (TbpB) is an attractive candidate vaccine antigen. However, it exhibits high levels of antigenic variability, posing a significant obstacle in evoking a broadly protective immune response.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!